These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38220218)

  • 1. An open, multicenter, exploratory study of apatinib mesylate maintenance therapy for recurrent/metastatic head and neck squamous cell carcinoma (ChiCTR1800019375).
    Wei J; Su J; Wang J; Jia X; Zhao Q; Shi W; Wang H; Zheng Z; Jiang X
    Head Neck; 2024 Apr; 46(4):915-925. PubMed ID: 38220218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study.
    Liu Z; Zheng Z; Dong L; Guo X; Jia X; Wang J; Meng L; Cui X; Jiang X
    Sci Rep; 2022 Oct; 12(1):18327. PubMed ID: 36316341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study.
    Xia X; Jiang W; Qi W; Hong B; Zhao W
    Oncol Res Treat; 2020; 43(12):649-655. PubMed ID: 33045704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study.
    Yang H; Chen M; Mei Z; Xie C; Zhou Y; Qiu H
    Cancer Med; 2021 Jul; 10(13):4282-4290. PubMed ID: 33987959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
    Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
    Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma.
    Chen TH; Pan YY; Lee TL; Wang LW; Tai SK; Chu PY; Lo WL; Wu CH; Yang MH; Chang PM
    BMC Cancer; 2022 Dec; 22(1):1336. PubMed ID: 36539738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined all-trans retinoic acid with low-dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single-center, secondary analysis of a phase II study.
    Ye L; Zhang L; Li R; Pan X; Li J; Dou S; Jiang W; Wang C; Chen W; Zhu G
    Cancer Med; 2023 Apr; 12(8):9144-9155. PubMed ID: 36734294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial.
    Guigay J; Le Caer H; Ferrand FR; Geoffrois L; Saada-Bouzid E; Fayette J; Sire C; Cupissol D; Blot E; Guillet P; Pavillet J; Bozec L; Capitain O; Rolland F; Debourdeau P; Pointreau Y; Falandry C; Lopez S; Coutte A; Chatellier T; Dalloz P; Ortholan C; Michel C; Lacas B; Cheurfa N; Schwob D; Bourhis J; Mertens C; Aupérin A;
    Lancet Healthy Longev; 2024 Jun; 5(6):e392-e405. PubMed ID: 38759667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.
    Guo Y; Ahn MJ; Chan A; Wang CH; Kang JH; Kim SB; Bello M; Arora RS; Zhang Q; He X; Li P; Dechaphunkul A; Kumar V; Kamble K; Li W; Kandil A; Cohen EEW; Geng Y; Zografos E; Tang PZ
    Ann Oncol; 2019 Nov; 30(11):1831-1839. PubMed ID: 31501887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
    Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
    Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11).
    Chu L; Chen Y; Liu Q; Liang F; Wang S; Liu Q; Yu H; Wu X; Zhang J; Deng J; Ai D; Zhu Z; Nie Y; Zhao K
    Oncologist; 2021 Jun; 26(6):e925-e935. PubMed ID: 33393167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting.
    Leng J; Li DR; Huang LM; Ji XH; Wang DL
    Medicine (Baltimore); 2019 Sep; 98(36):e16967. PubMed ID: 31490378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.
    Desilets A; Pfister DG; Stein S; Wong W; Sherman EJ; Fetten J; Hung TKW; Kriplani A; Dunn LA; Ho AL; Michel LS
    Oral Oncol; 2024 Jul; 154():106861. PubMed ID: 38795600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
    Ruan X; Liang JH; Pan Y; Cai R; Zhang RJ; He Z; Yang X; Niu Z; Jiang W
    Cancer; 2021 Sep; 127(17):3163-3171. PubMed ID: 34043812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and feasibility of Apatinib and S-1 as a novel oral induction therapy in locally advanced head and neck squamous cell carcinoma: an exploratory phase 2 open-label, single-arm trial.
    Jiang W; Li R; Zhang L; Dou S; Ye L; Shao Z; Wu S; Dong M; Li J; Zhu G
    Front Oncol; 2023; 13():1072538. PubMed ID: 37251944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
    Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
    Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma.
    Okamoto I; Tsukahara K; Sato H
    Sci Rep; 2022 Feb; 12(1):2025. PubMed ID: 35132165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Taguchi J; Shimizu Y; Ariga S; Goda T; Ohhara Y; Honma R; Noguchi T; Takeuchi S; Kinoshita I; Amano T; Mizumachi T; Kano S; Takahara M; Abe T; Homma A; Dosaka-Akita H
    Int J Clin Oncol; 2021 Jan; 26(1):51-58. PubMed ID: 32996023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.